meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/adv melanoma (mML)
mML - (neo)adjuvant (NA)
mML - NA - all population
9
mML - NA - PDL1 positive
1
mML - 1st line (L1)
mML - L1 - all population
7
mML - L1 - BRAF mutant
2
mML - L1 - BRAF wild
3
mML - 2nd line (L2)
mML - L2 - all population
11
mML - L2 - BRAF mutant
1
mesothelioma (MS)
immune chekpoint inhibitors
anti-PD-(L)1
pembrolizumab based treatment
pembrolizumab alone
versus all
vs non active control
vs placebo
All patients
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
DMFS
RFS (extension)
RFS/DFS
DMFS
mML - NA - PDL1 positive
metastatic/adv melanoma (mML)
mML - (neo)adjuvant (NA)
mML - NA - PDL1 positive
versus placebo
pembrolizumab alone vs. placebo
1
-1435 [-2083; -786]
/10000
138/428 vs. 198/425
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open